Benazepril, an angiotensin converting enzyme inhibitor: drug interaction with salbutamol and bronchial response to histamine in normal subjects.

Author(s): Bauer KG, Brunel P, Nell G, Quinn G, Kaik GA

Affiliation(s): Department of Clinical Pharmacology, University of Vienna Medical School, Austria.

Publication date & source: 1997-12, Br J Clin Pharmacol., 44(6):573-5.

Publication type: Clinical Trial; Randomized Controlled Trial

AIMS: To investigate the effect of the angiotensin converting enzyme inhibitor, benazepril, on pulmonary function. METHODS: We investigated the influence of benazepril, on lung function and the interaction with inhaled salbutamol (0.1 to 6.6 mg) and histamine (0.03 to 30.69 g l-1) in normal subjects. Benazepril 20 mg, salbutamol 8 mg, propranolol 160 mg, and placebo were given orally once daily over 10 days. RESULTS: On day 8, there was no difference in the area under the salbutamol dose-response curves between benazepril, placebo and oral salbutamol (P > 0.05), propranolol shifted the curves to the right (P < 0.05). On day 10, histamine challenge resulted in following PD35sGaw values (geometric mean and 95% CI): with placebo 1.02 (0.95-1.09) g l-1, benazepril 1.04 (0.99-1.08), salbutamol 1.19 (1.13-1.25), propranolol 0.57 (0.50-0.65). CONCLUSIONS: Benazepril had no influence on baseline lung function, caused no interaction with inhaled salbutamol and the bronchial response to histamine was similar to placebo. However, our findings in normal subjects cannot be extrapolated automatically to asthmatics.